Green Alpha Advisors LLC Makes New $773,000 Investment in Illumina, Inc. $ILMN

Green Alpha Advisors LLC acquired a new position in Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 4,396 shares of the life sciences company’s stock, valued at approximately $773,000.

Several other hedge funds also recently made changes to their positions in ILMN. Allworth Financial LP bought a new stake in shares of Illumina in the second quarter valued at approximately $1,051,000. Greenspring Advisors LLC bought a new position in Illumina during the 2nd quarter worth $264,000. B. Metzler seel. Sohn & Co. AG bought a new position in shares of Illumina in the second quarter worth $982,000. Vise Technologies Inc. acquired a new position in Illumina in the second quarter valued at about $911,000. Finally, OVERSEA CHINESE BANKING Corp Ltd bought a new stake in Illumina during the second quarter worth about $6,711,000. 89.42% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ILMN. Leerink Partners increased their price objective on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. TD Cowen raised their target price on shares of Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Canaccord Genuity Group boosted their price target on Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a report on Monday, August 3rd. Royal Bank Of Canada increased their price objective on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Finally, Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $188.40.

Insider Buying and Selling at Illumina

In other news, Director Keith A. Meister sold 457,858 shares of Illumina stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 2,095,958 shares of company stock valued at $401,720,974. Corporate insiders own 2.90% of the company’s stock.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Illumina Stock Performance

Shares of ILMN stock opened at $219.40 on Friday. The firm has a 50 day moving average of $188.01 and a 200-day moving average of $152.44. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $220.43. The company has a market cap of $33.13 billion, a price-to-earnings ratio of 40.93, a price-to-earnings-growth ratio of 3.00 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the prior year, the firm earned $1.19 EPS. The business’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.